Baidu
map

MedSci赞助2010细胞治疗研究进展与临床应用前沿研讨会

2010-09-24 MedSci原创 MedSci原创

2010细胞治疗研究进展与临床应用前沿研讨会 http://www.bioon.com/z/Cell-therapies/           本次大会嘉宾云集,包括巴德年,吴祖泽,陆道培,曹雪涛,付小兵,谷涌泉,陆树良,郭亚军,裴雪涛,陈虎,张叔人,向荣,程涛,宋永平,裴端卿,韩明哲,徐国彤,韩忠朝,夏建川,陈东

2010细胞治疗研究进展与临床应用前沿研讨会

http://www.bioon.com/z/Cell-therapies/  

        本次大会嘉宾云集,包括巴德年,吴祖泽,陆道培,曹雪涛,付小兵,谷涌泉,陆树良,郭亚军,裴雪涛,陈虎,张叔人,向荣,程涛,宋永平,裴端卿,韩明哲,徐国彤,韩忠朝,夏建川,陈东风,李忠义,刘斌,有5位院士参与,多达20余位嘉宾莅临,也是国内首届细胞治疗领域专业会议,在国内外引起强烈反响。

        昨天在天津召开,参会人员超过500余人,是细胞治疗领域首次学术会议,也预示着细胞治疗领域的快速发展。MedSci有幸赞助此次盛会,并与予会专家和参会代表进行较为深入地沟通和交流。

        近些年来,随着细胞生物学尤其是干细胞研究的快速发展,全球在细胞治疗领域已经进行了大量的探索,取得了一系列的令人振奋的成果,且部分基础研究成果已经在心血管系统疾病、神经系统疾病、肌肉骨骼相关疾病、糖尿病等的临床试验中得到应用。细胞治疗克服了临床常规治疗的局限性,为人类疾病的治疗打开了全新的思路。我国的细胞治疗也出现了一些喜人的临床成果,甚至有发达国家的患者主动来到中国接受治疗,体现了我国细胞治疗在世界上的重要地位。

        然而,细胞治疗作为一种新型的人类疾病治疗手段,我们还有很多方面需要进行深入地探讨,比如哪些是适合移植的最佳细胞类型,细胞移植的数量和间隔,移植的部位,移植后细胞在体内的具体机制等确切的作用机制等,以及临床应用的有效性和安全性依然是目前科学家关注和争论的焦点。

        此次研讨会正是为了促进细胞治疗基础研究和临床应用而举办,会议受到了国家科技部、卫生部、国家基金委的关注,并邀请细胞治疗基础和临床研究的顶级专家,针对细胞治疗伦理、细胞制品质量控制、肿瘤的树突状细胞(DC)治疗、T细胞过继免疫治疗、干细胞移植治疗、基因修饰化细胞治疗、微囊化细胞移植治疗等热门议题进行讨论,促进细胞治疗从基础研究到临床应用快速、有效地转化,建立研究与临床的有效沟通桥梁!

此次会议演讲嘉宾如下:

韩忠朝

国家干细胞工程技术研究中心...(详情)

巴德年

中国医学科学院
...(详情)

付小兵

解放军304医院
...(详情)

阮长耿

江苏省血液研究所
...(详情)

王正国

工程院医药卫生工程学部
...(详情)

洪涛

中国疾病预防控制中心
...(详情)

郭亚军

解放军总医院肿瘤中心 ...(详情)

陈虎

军事医学科学院附属医院...(详情)

张叔人

中国医学科学院肿瘤研究所
...(详情)

向荣

南开大学医学院
...(详情)

程涛

中国医学科学院血液学研究所
...(详情)

黄平平

中国医学科学院血液病医院
...(详情)

陆树良

上海交大医学院附属瑞金医院
...(详情)

谷涌泉

首都医科大学宣武医院

...(详情)

夏建川

中山大学肿瘤防治中心
...(详情)

陈东风

重庆第三军医大学大坪医院
...(详情)

赞助企业如下:

         

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1835543, encodeId=4bc0183554341, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat May 28 05:05:00 CST 2011, time=2011-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994646, encodeId=fb461994646db, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Oct 31 04:05:00 CST 2010, time=2010-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380300, encodeId=f676138030002, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Sep 26 06:05:00 CST 2010, time=2010-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605564, encodeId=6dd6160556467, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 26 06:05:00 CST 2010, time=2010-09-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1835543, encodeId=4bc0183554341, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat May 28 05:05:00 CST 2011, time=2011-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994646, encodeId=fb461994646db, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Oct 31 04:05:00 CST 2010, time=2010-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380300, encodeId=f676138030002, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Sep 26 06:05:00 CST 2010, time=2010-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605564, encodeId=6dd6160556467, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 26 06:05:00 CST 2010, time=2010-09-26, status=1, ipAttribution=)]
    2010-10-31 kcb069
  3. [GetPortalCommentsPageByObjectIdResponse(id=1835543, encodeId=4bc0183554341, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat May 28 05:05:00 CST 2011, time=2011-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994646, encodeId=fb461994646db, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Oct 31 04:05:00 CST 2010, time=2010-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380300, encodeId=f676138030002, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Sep 26 06:05:00 CST 2010, time=2010-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605564, encodeId=6dd6160556467, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 26 06:05:00 CST 2010, time=2010-09-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1835543, encodeId=4bc0183554341, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sat May 28 05:05:00 CST 2011, time=2011-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994646, encodeId=fb461994646db, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Sun Oct 31 04:05:00 CST 2010, time=2010-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380300, encodeId=f676138030002, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Sep 26 06:05:00 CST 2010, time=2010-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605564, encodeId=6dd6160556467, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Sep 26 06:05:00 CST 2010, time=2010-09-26, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map